Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma
Clinical trial NCT06353022 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06353022
- Sponsor
- Nantes University Hospital
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-06-26
- Primary completion
- 2028-04-26
- Enrollment
- 103
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.